Form 4: Versant Sells Over 1.6M LAVA Therapeutics Shares

Versant Venture Capital VI, L.P. and its affiliates reported the sale of over 1.6 million shares of LAVA Therapeutics NV common stock across three days in September 2025.

Summary

• Versant Venture Capital VI, L.P. and its affiliated entities, including Versant Vantage I, L.P., reported multiple sales of LAVA Therapeutics NV (LVTX) common stock.
• A total of 1,684,434 shares were sold over three trading days: September 16, 17, and 18, 2025.
• The sales were executed at weighted average prices ranging from $1.4418 to $1.5332 per share.
• These transactions were conducted pursuant to a Rule 10b5-1(c) plan, indicating pre-scheduled sales.
• Following these transactions, the reporting persons collectively beneficially own 2,903,403 shares of LAVA Therapeutics NV.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a major investor and director, even if pre-planned. The declining average sale price over the transaction days further contributes to a cautious outlook. While 10b5-1 plans are common, a large reduction in stake by a key investor is generally not a positive signal for the stock.

Positives

• The sales were conducted under a Rule 10b5-1(c) plan, suggesting a pre-planned divestment strategy rather than an immediate reaction to negative company news.

Negatives

• A significant insider, a 10% owner and director, has reduced its stake in the company by over 1.6 million shares.
• The average sale prices decreased over the three days, from $1.5332 on September 16 to $1.4418 on September 18, indicating a declining trend in the stock price during the sale period.

Risks

• Significant insider selling by a major institutional investor and director could signal a lack of confidence in the company's future prospects or a strategic shift in their investment portfolio.
• The declining average sale price over the transaction dates suggests potential downward pressure on the stock.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding LAVA Therapeutics NV's future performance or strategic direction.

Management Comments

• The filing does not contain notable quotes or paraphrased statements from company management, only the signature of Max Eisenberg as Chief Operating Officer for the reporting Versant entities.

Industry Context

Insider selling by a significant venture capital firm, especially one with director representation, can be viewed by the market as a signal, particularly in the biotechnology sector where early-stage investors often exit positions as companies mature or strategic objectives shift. While these sales were pre-planned, the consistent reduction in stake by a major investor could be interpreted as a re-evaluation of LAVA Therapeutics' long-term potential or a portfolio rebalancing.

Comparison to Industry Standards

• As a Form 4 filing, it primarily reports insider transactions and does not provide financial results for comparison. However, significant insider selling by a venture capital firm that is also a 10% owner and director, such as Versant's divestment from LAVA Therapeutics, is generally viewed with caution by investors.
• In the biotech industry, such sales by early-stage investors are common as companies progress, but the scale and timing relative to company milestones would typically be scrutinized against peers like Flagship Pioneering's or OrbiMed's portfolio management strategies, where similar divestments are often observed after significant value creation or strategic shifts.

Related Party Transactions

• Versant Venture Capital VI, L.P. and its affiliated entities are 10% owners and have director representation on LAVA Therapeutics NV's board, making these sales related-party transactions.

Stakeholder Impact

• Shareholders: May interpret the significant insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
• Company Management: Could face questions regarding the implications of a major investor reducing its stake.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for LAVA Therapeutics NV.

Key Dates

Recommendation

The significant insider selling by Versant Venture Capital VI, L.P. and its affiliates, who are 10% owners and have director representation, is a strong negative signal. While these sales were pre-planned under a Rule 10b5-1(c) plan, the sheer volume of shares divested (over 1.6 million) and the declining average sale price over the transaction period suggest a lack of conviction or a strategic exit by a major institutional investor. This action could lead to further downward pressure on the stock price and erode investor confidence, making a 'sell' recommendation appropriate for investors seeking to mitigate potential losses.

Keywords

LAVA Therapeutics, LVTX, Versant Venture Capital, Insider Selling, Form 4, Biotechnology, Venture Capital, Stock Sale, Beneficial Ownership